Compare Dow Inc (DOW) vs Johnson & Johnson (JNJ) Price & Performance

DOW trades at $28.59, up 2.95% today, with a bullish technical signal despite mixed indicators. The stock shows deteriorating fundamentals with negative net income margin (-3.13%) and ROE (-7.86%) in 2025, though recent quarters have beaten EPS expectations. Cash flow trends show operational challenges with declining operating cash flow from $7.5B in 2022 to $1.0B in 2025, offset by increased financing activities.

The outlook remains cautious with analyst consensus at 'Hold' (55.55%) and $34.22 price target offering 20% upside. Key risks include persistent margin pressures, high debt levels (debt-to-asset ratio 29.87% in 2025), and cyclical chemical industry exposure. The dividend yield provides some support, but fundamental improvement is needed for sustained recovery.

Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.

JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.